About Allegro Diagnostics
Allegro Diagnostics is a company based in Maynard (United States) founded in 2006 was acquired by Veracyte in September 2014. Allegro Diagnostics has raised $9.4 million across 4 funding rounds from investors including HHS, Veracyte and Boston University. Allegro Diagnostics operates in a competitive market with competitors including Strand Life Sciences, Invitae, Genome Medical, Myriad Genetics and Fulgent Genetics, among others.
- Headquarter Maynard, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Allegro Diagnostics
Allegro Diagnostics has successfully raised a total of $9.4M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $5.4 million completed in July 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Allegro Diagnostics
Allegro Diagnostics has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Veracyte and Boston University.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Seed and early stage venture fund investing in North America and Canada
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Cancer research is conducted and supported by the institute.
|
Locked | Locked | Locked |
Investor details for Allegro Diagnostics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Allegro Diagnostics
Investment portfolio details for Allegro Diagnostics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Allegro Diagnostics
Detailed financials for Allegro Diagnostics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Allegro Diagnostics Comparisons
Peer comparison for Allegro Diagnostics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Allegro Diagnostics
Allegro Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Strand Life Sciences, Invitae, Genome Medical, Myriad Genetics and Fulgent Genetics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery
|
|
| Locked | Locked | Locked |
Home-based genetic tests for detecting diseases are provided to individuals.
|
|
| Locked | Locked | Locked |
Genomic testing services are provided clinically and directly to consumers.
|
|
| Locked | Locked | Locked |
Molecular diagnostics and personalized medicine for cancer are developed.
|
|
| Locked | Locked | Locked |
Provider of genetic testing services for carrier screening cardiovascular diseases, epilepsy and cancer
|
|
| Locked | Locked | Locked |
Diagnostics and risk assessment solutions for lung cancer are developed.
|
Detailed competitors of Allegro Diagnostics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Allegro Diagnostics
Complete news archive for Allegro Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Allegro Diagnostics
Allegro Diagnostics was founded in 2006 and raised its 1st funding round 2 years after it was founded.
Allegro Diagnostics is headquartered in Maynard, United States. It is registered at Maynard, Massachusetts, United States.
Allegro Diagnostics is a funded company, having raised a total of $9.4M across 4 funding rounds to date.
Allegro Diagnostics was founded in 2006 in Maynard, United States, within the genomics and diagnostics sector. Focus was placed on developing tests for lung cancer, including the flagship BronchoGen assay. Next-generation sequencing was employed to assess inconclusive lung nodules from bronchoscopies, determining if they were cancerous or benign. The company was acquired by Veracyte in September 2014 for 21 million.
Allegro Diagnostics's top competitors include Strand Life Sciences, Fulgent Genetics and Biodesix.
Allegro Diagnostics has 6 investors. Key investors include HHS, Veracyte, Boston University, National Cancer Institute, and Kodiak Venture Partners.